Denali Therapeutics (DNLI) Revenue (2018 - 2023)

Denali Therapeutics (DNLI) has 6 years of Revenue data on file, last reported at $1.3 million in Q3 2023.

• On a quarterly basis, Revenue fell 62.46% year-over-year to $1.3 million in Q3 2023; TTM through Jun 2024 was $1.3 million, a 99.63% decrease from a year earlier, with the FY2023 full-year figure at $330.5 million, up 214.6% from the prior year.
• Revenue for Q3 2023 stood at $1.3 million, down from $294.1 million in the prior quarter.
• Over the last five years, Revenue for DNLI reached as high as $316.8 million in Q4 2020 and fell as low as $52000.0 in Q1 2020.
• Historically, Revenue has averaged $46.0 million across 5 years, with a median of $9.4 million in 2020.
• Across the five-year window, Revenue slumped 98.76% in 2020 and jumped 15134.62% in 2021, its largest moves.
• Year by year, Revenue stood at $4.7 million in 2019, then surged by 6681.04% to $316.8 million in 2020, then sank by 84.64% to $48.7 million in 2021, then sank by 79.45% to $10.0 million in 2022, then tumbled by 87.33% to $1.3 million in 2023.
• Per Business Quant data, the three most recent Revenue figures were $1.3 million in Q3 2023, $294.1 million in Q2 2023, and $35.1 million in Q1 2023.